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Structure-Based Design on the Way to New Anti-Infectives
Anna Katharina Herta Hirsch
7.1
Introduction
With an estimated 300–500 million new infections and three million deaths
annually, malaria and tuberculosis undoubtedly still pose a major health concern
[1]. The need for the development of novel therapeutic approaches is ever-growing
in light of the emergence of multi-drug-resistant parasites [2]. How can a new drug
be identiﬁed?
First, a lead compound, that is, a molecule with a promising biological activity
that does not yet fulﬁll all the requirements but represents the starting point on
the way to a new drug, has to be identiﬁed. A number of different strategies exist
to achieve this goal:
• High-throughput screening (HTS) of a large library of small molecules is of
particular interest in cases in which no structural information or characterization
of the biological target is available. The majority of lead compounds still comes
from hits identiﬁed by HTS [3].
• Virtual screening has established itself as an alternative or complementary
approach to classical HTS. Potentially active and/or drug-like compounds are
selected from a library of compounds, using elaborate docking and scoring
functions [4].
• Combinatorial chemistry is useful for the formation of large, small-molecule
libraries. However, this approach is less effective for generating a great deal of
structural diversity.
• Nature can be of help by providing a rich and diverse source of structural
inspiration [5]. The scaffold of a natural product, displaying interesting biological
properties, could be developed into a new drug.
• Structure-based design, a comparatively new ﬁeld, has established itself in pharma-
ceutical research as a valuable alternative to traditional screening; the X-ray crystal
structure of a target enzyme is used as a basis for lead compound identiﬁcation
and optimization. The increasing number of leads, identiﬁed and/or optimized
using this rational approach, used for the development of new drugs illustrates
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this fact [6]. Until now, this strategy has been mainly used in the later stages of
lead optimization.
The last mentioned strategy will be employed for the purposes of this project. The
aim of this approach is to identify synthetically accessible target molecules, with
optimal stereoelectronic properties that are complementary to the binding site of
the target enzyme and show minimal or no repulsive interactions when complexed
to the enzyme. The identiﬁcation of promising leads is aided by the medicinal
chemist’s understanding ofmolecular recognition. While hydrophobic interactions
between a lead and an enzyme are the main driving force for complexation,
H-bonding interactions account for selectivity (Figure 7.1). Later stages of drug
development are not the subject of this chapter.
To determine the biological activity of a potential lead compound, a new biological
target [7], that is, an enzyme or receptor that upon interference by the ligand/drug
has an impact on the disease causing pathogen in the desired way, has to be
identiﬁed. In an ideal case, the target is essential for the pathogen and not present
in humans, thereby precluding any selectivity issues. Isoprenoids are an essential
class of natural products, requiring the essential precursors isopentenyl diphos-
phate (IPP, 1) and dimethylallyl diphosphate (DMAPP, 2) for their biosynthesis
(Scheme 7.1). Until recently, only one route to the universal isoprenoid precursors
was known, the so-called mevalonate pathway, using acetyl-coenzyme A as the
only building block [8]. A completely distinct alternative to this well-established
biosynthetic route, now known as the nonmevalonate pathway, was discovered in
the early 1990s, starting from pyruvate (3) and glyceraldehyde 3-phosphate (4) [9].
Interestingly, this biosynthetic pathway is exclusively used by a number
of pathogens such as the malarial parasite Plasmodium falciparum and the
tuberculosis-causing Mycobacterium tuberculosis and not by higher eukaryotes
(e.g., humans), which means that inhibition of the constituent enzymes of the
nonmevalonate pathway affects and kills only the parasites, leaving the patient
untouched (Scheme 7.1). Thus, this pathway has provided a rich source of new,
highly attractive drug targets.
To illustrate the use of a structure-based design cycle, the development of the
ﬁrst inhibitors of the kinase IspE of the nonmevalonate pathway is described below,








Figure 7.1 Schematic representation of structure-based inhibitor design.




















Scheme 7.1 Schematic representation of the biosynthesis
of the isoprenoid precursors IPP (1) and DMAPP (2). P =
phosphate group.
is brieﬂy presented with an overview of the known inhibitors of the constituent
enzymes. Subsequently, the chosen target, the kinase IspE, is introduced and its
structure is discussed in some detail. This will provide the basis for the rationale of
the design of the ﬁrst-generation inhibitors. Second, the active site is explored by
showing the possibility of applying concepts from supramolecular chemistry to an
enzymatic context. Finally, the development of water-soluble inhibitors is described
with the aim of obtaining an X-ray cocrystal structure to verify the proposed binding
mode.
7.2
Isoprenoids and the Nonmevalonate Pathway
There are more than 35 000 known isoprenoids, which fulﬁll a myriad of impor-
tant biological functions. Despite their striking structural diversity, all isoprenoids
are biosynthesized from the two simple ﬁve-carbon building blocks 1 and 2
(Scheme 7.1). This concept is also known as the isoprene rule [10]. The nonmeval-
onate pathway starts with the head-to-tail condensation of the two- and three-carbon
precursors 3 and 4. A total of seven enzymes catalyze the conversion of these start-
ing materials into the essential isoprenoid precursors 1 and 2. Fosmidomycin, an
inhibitor of the second enzyme of the pathway (IspC), has been shown to cure
malaria in rodents, thereby validating the constituent enzymes as drug targets [11].
This ﬁnding triggered research efforts aimed at the elucidation of the structures
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and mechanisms of the participating enzymes. As a result, detailed structural and
mechanistic data exist for most enzymes [12], setting the stage for lead generation
by structure-based design. A number of enzymes of the nonmevalonate pathway
have been chosen as targets to achieve this goal. The rather hydrophilic nature
of the active sites renders the development of low-molecular-weight inhibitors
challenging. Thus, it comes as no surprise that the few reported inhibitors ei-




The absence of known inhibitors, the fact that the kinase IspE belongs to the
nonmevalonate pathway, and the availability of an X-ray crystal structure make
the fourth enzyme of the pathway an ideal target for rational design of potent,
drug-like inhibitors without the use of the problematic phosphate or phosphonate
moieties. IspE (EC 2.7.1.148) employs adenosine 5′-triphosphate (ATP) and Mg2+
cations for the phosphorylation of the C(2)-hydroxyl group of 4-diphosphocytidyl-
2C-methyl-d-erythritol (5) to afford 4-diphosphocytidyl-2C-methyl-d-erythritol
2-phosphate (6, Scheme 7.2) [18].
This central reaction is the only ATP-dependent step of the whole biosynthetic
pathway. Sequence comparisons have shown that IspE belongs to the galactose/
homoserine/mevalonate/phosphomevalonate (GHMP) kinase superfamily [19].
7.2.2
Structure of IspE
In 2003, the ﬁrst crystal structures of IspE from Thermus thermophilus and
Escherichia coliwere solved, of the apoenzyme and of a ternary complex, respectively
[20, 21]. Recently, the crystal structure of Aquifex aeolicus IspE was solved as a com-
plex with a number of natural ligands [22], a synthetic substrate mimic [22], and
synthetic cytidine [23] as well as cytosine (Section 7.4) [24] derivatives. To date,
no crystal structure is available for IspE from a pathogen, for example, M. tu-
berculosis or P. falciparum. IspE generally crystallizes as a homodimer with each
monomer displaying the characteristic two-domain fold of the GHMP kinase su-
perfamily that consists of an ATP- and a substrate-binding domain. The dimer
clasps around a solvent-ﬁlled channel, featuring two active sites at either end
(Figure 7.2).
7.2.3
Active Site of IspE
The active site of E. coli IspE was used for modeling. It can be divided into
three main pockets: the ATP-, the cytidine 5′-diphosphate (CDP)-, and the methyl-
erythritol (ME)-binding pockets. Molecular modeling, using the program MOLOC











































































































































































































































































































































































































































Scheme 7.2 Simpliﬁed version of the nonmevalonate pathway.
AMP-PNP
5
Figure 7.2 Schematic representation of the ternary complex
of E. coli IspE, 5′-adenyl-β, γ -amidotriphosphate (AMP-PNP)
and the substrate 5, cocrystallized as a homodimer (Protein
Data Bank (PDB) code: 1OJ4) [20].












































Figure 7.3 Schematic representation of the four pockets of
the active site of E. coli IspE. The residues of the glycine-rich
loop were omitted for clarity.
[25], revealed that an additional small, hydrophobic pocket lies adjacent to the
CDP-binding site (Figure 7.3).
The ATP-binding pocket features a glycine-rich phosphate-binding loop,
typically displaying an adjacent positively charged N terminus of an α helix [20].
The adenine moiety is accommodated in a hydrophobic cleft lined by Val57, Val60,
Leu66, Ile67, Lys96, and Met100. Numerous hydrophobic contacts offered by this
pocket certainly make a large contribution to the binding enthalpy, as predicted
by MOLOC. Additional stabilization is derived from a network of H bonds to
the nucleobase moiety. The ribose moiety of 5′-adenyl-β, γ -amidotriphosphate
(AMP-PNP) is solvent-exposed and does not show any contacts with the
protein.
The CDP-binding pocket accommodates the cytosine moiety in a π sandwich,
consisting of the side chains of Tyr25 and Phe18 held in place by – stacking
interactions. The ribose moiety beneﬁts from stabilization by a pseudo-π sandwich
that is composed of the aromatic side chain of Tyr25 and the aliphatic Pro182. A
pseudo-π sandwich can be deﬁned as a π sandwich, in which one of the two aromatic
rings is replaced by an aliphatic ring. His26 is a key residue for the recognition of
cytosine, which involves a total of three H-bonding interactions. The ribose and
phosphate groups are stabilized by a number of solvent-mediated interactions and
a H bond from the side chain of Tyr25 (Figure 7.4).
IspE was shown to have high substrate speciﬁcity [21]. Hence, the cytosine
moiety must play a key role in substrate recognition and thus selectivity, providing
the starting point for the structure-based design of the ﬁrst-generation inhibitors
(Section 7.3).












Figure 7.4 (a) CDP- and ME-binding and the small,
hydrophobic pockets of E. coli IspE. (b) Active site of E. coli
IspE (PDB code: 1OJ4) [20]. Color code: protein skeleton: C:
gray; skeleton of 5: C: green; O: red; N: blue; P: orange.
7.3
Targeting the CDP-Binding Pocket of IspE
7.3.1
Design
Careful examination of the active site revealed the CDP-binding pocket to be more
attractive as a target for inhibitor design than the other binding pockets for a
number of reasons. A perfect setup for a double π sandwich and other recognition
features should endow potential inhibitors with higher selectivity. Furthermore,
given themyriad of proteins that use ATP as a cofactor, inhibitors designed to target
the ATP-binding pocket bear a high risk of selectivity issues. Given that neither
substrate nor cofactor bind to the adjacent, hydrophobic pocket, presumably, both
afﬁnity and selectivity could be gained by occupying it. As this small cavity lies
adjacent to the CDP-binding pocket, potential inhibitors should be designed to
occupy both the CDP-binding pocket and the newly discovered subpocket, leaving
the hydrophilic ME- as well as the ATP-binding pockets unoccupied.
In a ﬁrst round of design, cytosine was chosen as a central scaffold to posi-
tion potential inhibitors in the CDP-binding pocket. According to modeling, the
nucleobase moiety was predicted to be sandwiched between Tyr25 and Phe185.
By analogy to the natural substrate 5, the cytosine moiety was postulated to be
able to form H bonds to His26. It was concluded that the central platform should
be decorated with a suitable ribose analogue at the N(1) position, which should
be held in place by the pseudo-π sandwich and a vector designed such that its
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substituent would be placed in the hydrophobic subpocket. If this were to be
achieved, numerous hydrophobic interactions would result. By connecting the
linker to the C(5) position, it should serve to address the catalytically essential
residues Lys10 and Asp141. Because of the modular design, the different compo-
nents, that is the ribose analogue, the vector, and the central scaffold, should be
easy to vary and optimize (Figure 7.5a).
7.3.1.1 Possible Ribose Analogues
As ribose analogues, both heteroalicyclic and aromatic rings can be envis-
aged to ﬁll the space provided by the pseudo-π sandwich (Figure 7.5b, com-
pounds of type 7 and 8). Introduction of a saturated ring featuring a sulfur
atom, for example, a tetrahydrothiophenyl ring, presumably would enable an
additional sulfur–aromatic interaction with the phenolic ring of Tyr25 [27].
Modeling predicted both enantiomers of a tetrahydrothiophenyl derivative to bind
with similar strength due to the conformational ﬂexibility of ﬁve-membered rings.
Four questions need to be answered regarding the choice of the ribose analogue:
(i) Which is the ideal ring size? (ii) Is an aromatic or an aliphatic system favored?
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Figure 7.5 (a) Modular design of
ﬁrst-generation inhibitors. (b) Ribose ana-
logues, (c) different vectors, and (d) sulfone
substituents envisaged for ﬁrst-generation
inhibitors. aclogP values (calculated
partitioning coefﬁcient) were calculated with
the program ACD/LogP [26]. The tetrahy-
drothiophenyl and the tetrahydrofuranyl
derivatives of type 7 and 8, respectively, are
chiral.
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7.3.1.2 Design of the Vector
For the vector, a propargylic sulfonamide substituent at the C(5) position of cytosine
was envisaged, which displays three attractive features. First, the alkyne ensures
a certain rigidity and linearity. Second, N-substituted sulfonamides are known
to prefer a conformation in which the lone pair of the nitrogen atom bisects
the O–S–O angle, resulting in a staggered arrangement [28]. In its preferred
conformation, the sulfonamide is expected to form ionic H bonds to the side chains
of Lys10 and Asp141. Finally, small complementary sulfone substituents (R2 =
Et, Figure 7.5a), should orient directly into the subpocket. However, before this
part of the vector is optimized (Section 7.3.4), the importance of the sulfonamide’s
contribution to afﬁnity should be evaluated (Section 7.3.3).
An exemplary inhibitor of type 7 features a tetrahydrothiophenyl ring as a ribose
mimic (R1) and an ethyl group as a sulfone substituent (R2) (Figure 7.5b). According
to modeling, the ligand should beneﬁt from H bonds to His26, Lys10, and Asp141
as well as from the postulated sulfur–aromatic interaction (Figure 7.6a). An overlay
of the natural substrate 5 and the potential inhibitor showed the sulfone moiety
to be almost perfectly superimposed with the C(2)-hydroxyl group that is to be
phosphorylated (Figure 7.6b).
The synthesis of the ﬁrst representative of the ﬁrst-generation inhibitors was
achieved using a convergent strategy based on the Sonogashira cross-coupling
reaction [29, 30]. With the synthetic route in place, the optimization of both
modules of the inhibitors could be initiated in parallel.
7.3.2
Optimization of the Ribose Analogue
It was envisaged to introduce a number of different ribose analogues (Figure 7.5b).
Different ring types had to be tested: saturated, aromatic, or heteroaromatic rings,
all of which should be directly attached to the N(1) of the nucleobase (ligands of
















Figure 7.6 (a) MOLOC-generated molecular model of
the exemplary inhibitor in the active site of E. coli IspE
(PDB code: 1OJ4) [20]. (b) Superposition of the potential
inhibitor and the natural substrate 5. Color code: S: yellow;
C skeleton of the inhibitor: cyan.
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of cytosine and the ribose analogue needed to be evaluated both for aliphatic and
(hetero-)aromatic substituents (compounds of type 8). In addition, it was deemed
important to test an acyclic ribose mimic, featuring an ester group. Replacement
of the sulfur atom of the tetrahydrothiophenyl ring of the exemplary inhibitor by a
methylene moiety to afford a cyclopentyl ring as a ribose analogue was expected to
yield information on the postulated sulfur–aromatic interaction. Synthesis of this
set of potential inhibitors was achieved using similar synthetic routes [24, 29].
Using the established photometric assay to determine the activity of potential
inhibitors against IspE, the IC50 and Ki values for all new ligands were determined
(Table 7.2) [24, 29, 31]. A competitive mechanism with respect to substrate binding
was assigned to most ligands. In a few cases, however, a mixed competitive
(Kic)–uncompetitive (Kiu) mode of inhibition was found. In agreement with the
observation that small cytosine derivatives possess remarkably low water solubility
[24], none of the inhibitors showed high water solubility, despite the low calculated
partitioning coefﬁcient (clogP) values (Figure 7.5b).
The results obtained are highly satisfactory: First, as no inhibitors of IspE
had been described at the onset of this design cycle, obtaining the ﬁrst active
compounds with Ki values in the upper-nanomolar range constitutes an important
achievement. Second, inhibition was possible in the absence of a phosphate or
phosphonate group. The ligands described constitute the ﬁrst example of potent,
drug-like inhibitors of an enzyme of the nonmevalonate pathway. Furthermore,
variation of the ribose mimic has a clear effect on afﬁnity, that is, structure–activity
relationships (SARs) could be observed. A methylene-bridged tetrahydrofuranyl
ring is the poorest ribose substitute with a double-digit micromolar Ki value.
Introduction of a methylene-bridged aromatic ring (benzyl) or an open alkyl chain
bearing an ester moiety as a ribose mimic clearly also has a negative effect on
afﬁnity. However, it seems that a methylene-bridged ring is tolerated as long as it
is not too bulky: the methylene-bridged cyclobutyl and pyrazolyl derivatives feature
similar afﬁnities to that of the inhibitor bearing a cyclopentyl ring directly attached
to N(1) of cytosine. On the basis of the afﬁnities, there does not seem to be any
Table 7.2 Inhibitory activities (E. coli IspE) of compounds
of type 7 and 8.
Ribose analogue Kic (µM)a
Tetrahydrothiophenyl 0.29 ± 0.1
Cyclopentyl 1.5 ± 0.2
Cyclobutylmethyl 1.5 ± 0.2
CH2–3-pyrazolyl 1.6 ± 0.1
Benzyl 3.7 ± 0.5b
CH2CO2Et 4.2 ± 0.6c
CH2–2-tetrahydrofuranyl 32.3 ± 2.8
aThe IC50 values can be found in 24, 29, 30.
bMixed inhibition: Kiu = 23.5 ± 7.1 µM.
cMixed inhibition: Kiu = 21.6 ± 6.2 µM.
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signiﬁcant difference between a heteroaromatic ring such as pyrazolyl and the
alicyclic cyclopentyl ring. However, if clogP values are taken into account, the
latter inhibitor is signiﬁcantly more lipophilic; hence, the resulting more favorable
partitioning from the aqueous buffer into the less polar protein environment could
partially account for its afﬁnity. This implies that heteroatoms afford some afﬁnity.
Finally, the tetrahydrothiophenyl ring is the best ribose mimic, affording the
lowest Ki value. Presumably, its improved afﬁnity could be ascribed to the favorable
sulfur–aromatic interaction. This interaction was quantiﬁed when comparing
the afﬁnities of the tetrahydrothiophenyl derivative with an inhibitor bearing the
same sulfone substituent (cyclopropyl) and a cyclopentyl ring as a ribose analogue.
The afﬁnity is lowered by a factor of ﬁve, corresponding to a free-enthalpy increase
of G300 K ≈ 1 kcalmol−1, in agreement with published data [27]. Both rings
beneﬁt from stabilization by the pseudo-π sandwich. Thus, the higher afﬁnity
could be explained by favorable interactions of the phenolic side chain and the
sulfur atom of the sandwiched ring.
7.3.3
Importance of the Vector
Before optimizing the propargylic sulfonamide vector, its signiﬁcance has to be
conﬁrmed. According to modeling, the sulfonamide group forms two H bonds
to Lys10 and Asp141. To verify this prediction experimentally, four derivatives
featuringmodiﬁed vectors and established ribose analogueswere designed and syn-
thesized (Figure 7.5c): (i) The N-methylated derivative of the most potent inhibitor,
featuring a cyclopropyl ring as sulfone substituent and a tetrahydrothiophenyl ring
as ribose analogue, served to quantify the importance of the ionic H bond between
the sulfonamide NH and the side chain of Asp141. (ii) Different propargyl amine
derivatives [compounds of type (±)-9] as well as propargyl alcohol derivative 10
were envisaged to evaluate the effect of substituting the sulfonamide altogether.
The set of target molecules were synthesized following similar routes [24].
Using the established enzymatic assay, the IC50 and Ki values of the potential
inhibitors were determined [24, 29, 31]. N-methylation of the sulfonamide nitrogen
atom clearly affected afﬁnity, illustrating the importance of the postulated ionic H
bond. Modeling showed the inhibitor to be still accommodated in the active site
without any repulsive interactions but with one less H bond. Comparison with the
most potent inhibitor enabled the quantiﬁcation of the postulated ionic H bond,
given that both ribose analogue and sulfone substituent remained unchanged.
The inhibitory potency was reduced by a factor of nearly 10 upon N-methylation
(Ki = 2.5 µM); thus, a contribution of up to G300 K = 1.3 kcalmol−1 to the
overall binding free enthalpy could be ascribed to this H bond alone (Figure 7.7a).
As expected, substitution of the sulfonamide moiety by heterocyclic amines led
to a decrease in inhibitory potency. A piperidyl-substituted derivative maintains the
highest afﬁnity (Ki = 4.7 µM). A possible explanation could be an ionic H bond
between the side chain of Asp141 and the piperidinium residue (Figure 7.7b).
According to modeling, the piperidinyl ring should be located at the entrance of the



























Figure 7.7 MOLOC-generated molecular model of (a) the
N-methylated and (b) the piperidinyl-substituted inhibitors
in the active site of E. coli IspE (PDB code: 1OJ4) [20].
Reproduced with permission from the Royal Society of
Chemistry.
small, hydrophobic pocket. In this way, a number of hydrophobic interactions with
the residues lining this cavity are still possible. A pyrrolidinyl-substituted derivative
was proposed to bind in a similar manner, displaying fewer hydrophobic contacts
because of its smaller ring. As a result, a decrease in binding afﬁnity was observed
(Ki = 11.8 µM). The alcohol 10 shows very weak afﬁnity for IspE; consequently,
no Ki value could be determined. This observation could be explained by the lack
of both a sulfonamide moiety and an alkyl substituent to beneﬁt from potential
interactions in the small, hydrophobic cavity.
In summary, important contributions of the sulfonamide moiety to the observed
binding afﬁnity were clearly conﬁrmed through this set of derivatives. With the
sulfonamide moiety validated as a good vector, the next logical step was therefore
the optimization of the sulfone substituent R (Figure 7.5d).
7.3.4
Optimization of the Filling of the Small, Hydrophobic Pocket
Inspired by the ﬁnding that optimal volume occupancy can be an important
contributor to afﬁnity [32], the small, hydrophobic pocket of IspE was carefully
examined. For this purpose, a series of derivatives of type (±)-11 and (±)-12
were designed, differing only in the sulfone substituent as shown in Figure 7.5d.
By keeping the scaffold, the vector and the ribose analogue constant, the effects
of different substituents on afﬁnity should be directly comparable. The target
molecules were readily synthesized [24]. The choice of substituents was guided
by the predictions made by molecular modeling and a concept from conventional
supramolecular chemistry – the ‘‘55% rule’’ – that was recently applied to enzymes
for the ﬁrst time [33].
7.3.4.1 The ‘‘55% Rule’’
Investigation of the optimal volume occupancy of the cavity space conﬁned by
capsular synthetic receptors by Mecozzi and Rebek led to the ‘‘55% rule,’’ stating
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that the most stable inclusion complex forms if 55 ± 9% of the apolar space is
occupied by the guest [34]. This concept holds true, from synthetic supramolecular
chemistry [35]. Recently, Zu¨rcher et al. applied it to the ﬁlling of a hydrophobic cavity
in the active site of the antimalarial target plasmepsin II [33]. The van-der-Waals
interactions in the cavity are not ideal at smaller packing coefﬁcients (PCs). At
higher PCs, however, large entropic losses, resulting from a decrease in themobility
of the binding partners, counteract enthalpic gains.
The small, hydrophobic pocket of E. coli IspE was estimated to be around
100 A˚3 by ﬁlling the pocket with a hydrocarbon network [34, 36]. Thus, the PCs
were calculated for different target molecules, which guided their design.
7.3.4.2 Evaluation of Inhibitors Featuring Different Sulfone Substituents
A series of potential inhibitors were subjected to the enzymatic assay. The inhibitory
activities as well as the calculated PCs for selected compounds are summarized in
Table 7.3.
A number of derivatives prepared feature Ki values in the nanomolar range. In
general, small alkyl chains with a maximum chain length of two carbon atoms or
cyclic alkyl substituents up to a ring size of ﬁve arewell suited to ﬁll the cavity; hence,
it is presumably more ﬂexible on the sides than at its bottom. The three-membered
ring seems to be ideal to ﬁll this lipophilic pocket. A 2,2,2-triﬂuoroethyl group almost
affords the same afﬁnity as the most potent inhibitor (featuring a cyclopropyl ring)
Table 7.3 Inhibitory activities (E. coli IspE) and PCs of
compounds of type (±)-11 and (±)-12.
Sulfone substituent Kic (µM) PC (%)
Cyclopropyl 0.29 ± 0.1 56
2,2,2-Triﬂuoroethyl 0.36 ± 0.1 n.d.
Isopropyl 0.52 ± 0.1 62
Cyclobutyl 0.56 ± 0 69
Ethyl 0.64 ± 0.1 45
Cyclopentyl 0.89 ± 0.1a 83
1,1,1-Triﬂuoromethyl 1.2 ± 0.3 n.d.
sec-Butyl 1.8 ± 0.3 n.d.
n-Hexyl 2.0 ± 0.3 107
Cyclohexyl 2.5 ± 0.4b 97
Methyl 2.6 ± 0.1 28
n-Butyl 8.0 ± 0.1 76
n-Propyl 8.2 ± 1.7c 61
Phenyl 16.3 ± 1.0 n.d.
aMixed inhibition: Kiu = 19.0 ± 9.2 µM.
bMixed inhibition: Kiu = 67.7 ± 35 µM.
cMixed inhibition: Kiu = 27.3 ± 11 µM.
n.d. = not determined.
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and is nearly twice as strong as the corresponding ethyl derivative (Figure 7.6a).
The afﬁnity of isopropyl- and cyclobutyl-substituted ligands is very similar to that
of the ethyl-substituted derivative; however, the alkyl residues seem to be slightly
too large for optimal volume occupancy, leading to a decrease in afﬁnity. As the
pocket is not properly ﬁlled by ligands with a smaller alkyl substituent (methyl),
the binding afﬁnity is reduced.
Evaluation of the set of derivatives in terms of their PCs showed binding afﬁnity
to correlate with volume occupancy: a cyclopropyl ring has a PC of 56% and the
lowest Ki value (Ki = 0.29 µM, Figure 7.8a).
Lower (28% for methyl and 45% for ethyl substituents) or higher PCs (62%
for isopropyl and 69% for cyclobutyl) are mirrored by weaker inhibition. A slight
increase in size of the sulfone substituent – that is, extension of the ethyl
substituent by one or two carbon atoms – led to a strong decrease in afﬁnity.
According to modeling, the n-propyl substituent might still ﬁt into the cavity
at the cost of adopting the energetically less favorable gauche conformation (PC
61%). The n-butyl substituent, however, cannot be accommodated by the pocket,
even when contorted. Thus, the propargylic sulfonamide linker could equally well
undergo a conformational change to direct this substituent out of the pocket
into solvent-exposed space. Larger substituents (PC > 80%), such as cyclopentyl,
cyclohexyl, or n-hexyl, were predicted to direct their alkyl substituents toward the
opposite direction, that is, toward the solvent (Figure 7.8b).
The increased lipophilicity (cf. clogP values) and the resulting more favorable
partitioning to the less polar protein environment from the aqueous buffer could
explain the increased binding afﬁnity.
In summary, by exploring the small, hydrophobic pocket, the afﬁnity of the
inhibitors was improved and another example for the application of the ‘‘55% rule’’







Figure 7.8 (a) van-der-Waals surfaces of the
cyclopropyl ring of the most potent inhibitor
of type (±)-11 and the protein in the small,
hydrophobic pocket. (b) MOLOC-generated
molecular model of the alkyl-substituted
inhibitors in the active site of E. coli IspE
(PDB code: 1OJ4) [20]. Color code: C
skeleton of the inhibitors: methyl, cyan;
ethyl, magenta; n-propyl, green; n-hexyl, light
pink.Reproduced with permission from the
Royal Society of Chemistry.
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7.3.5
Summary of the First-Generation Inhibitors
In conclusion, addressing the CDP-binding pocket was rewarded with the discovery
of the ﬁrst, potent, small-molecule inhibitors of IspE. The afﬁnity could be improved
through rational modiﬁcations of the lead compound, giving access to an extensive
set of SARs; for the time being, they provide the only indication that the proposed
binding mode is correct. X-ray-crystallographic studies had to be performed to
validate this hypothesis (Section 7.4).
7.4
X-ray Cocrystal Structure Analysis
Efforts were undertaken to obtain a cocrystal structure of the ﬁrst-generation
inhibitors and IspE. The kinase is very sensitive to crystallization conditions; even
traces of organic cosolvents are sufﬁcient to preclude crystal growth. Presumably,
because of the lack of water solubility of the ﬁrst-generation inhibitors, no cocrystal
structures could be obtained. Thus, a water-soluble derivative had to be designed
(Section 7.4.1). Provided it resembled the structure of the inhibitors in hand, it
could prove the binding mode of this class of compounds.
7.4.1
Design of Water-Soluble Inhibitors
Modeling as well as clogP values were used to guide the selection of promising
target molecules (Figure 7.9).
To improve the water solubility of the ﬁrst-generation inhibitors without a
concomitant decrease in afﬁnity, the sulfone substituent or the sulfonamide vector
(target molecules of type (±)-13) or the ribose analogue (ligands of type 14)
could be modiﬁed. Given that modestly potent inhibitors could be cocrystallized
(Section 7.2.2), the proposed series of target molecules looked promising as long

















Figure 7.9 Target molecules to improve the water solubility
of the ﬁrst-generation inhibitors.
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the vector, whereas the remaining three resulted from a modiﬁcation of the
ribose analogue. Introduction of a carboxylic acid or the corresponding ester
functionality, a morpholinyl, or an oxetanyl substituent should afford the desired
property. Oxetanes, in particular, were recently described to endow compounds
with improved physicochemical properties, namely, affording enhanced solubility
and decreased lipophilicity [37].
7.4.2
Enzyme Assays of Inhibitors Designed to be Water Soluble
Among the six compounds speciﬁcally prepared to obtain water-soluble inhibitors,
two (the morpholinyl-substituted sulfonamide (Ki = 13.1 µM) and the oxetanyl
derivative (compound 15, Figure 7.10b, Ki = 28.7 µM)) do not require addition
of dimethyl sulfoxide as a cosolvent to perform the enzyme assay [24]. While the
former still requires ethanol as a cosolvent, the latter is water soluble, setting the
stage for X-ray crystallographic studies (Section 7.4.3).
Water solubility was achieved at the expense of potency: the afﬁnity was decreased
by nearly two orders of magnitude, when replacing the tetrahydrothiophenyl ring
of the most potent inhibitor by the oxetanyl substituent of inhibitor 15. Because
of their poor afﬁnities, only the IC50 values of the carboxylic acid derivatives were
determined (upper micromolar range). The weak inhibitory potency of the mor-
pholinyl derivative lacking the sulfonamide moiety could be explained by the bad
match between the electronics of the morpholinyl moiety and the small, hydropho-
bic subpocket. Thus, introduction of an oxygen atom to the piperidinyl derivative of
type (±)-9 (Section 7.3.3), affording the corresponding morpholinyl-substituted lig-
and, resulted in a decrease in afﬁnity by almost a factor of nine. A similar decrease
in afﬁnity was observed when changing the sulfone substituent from cyclohexyl
(compound of type (±)-12) to morpholinyl. The poor afﬁnity of the carboxylic



























Figure 7.10 (a) Binding mode of inhibitor 15 in the
CDP-binding pocket of active site B (PDB code: 2VF3) [24].
(b) Structure of compound 15.
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7.4.3
Structural Analysis
The structure of the oxetanyl derivative 15 in complex with A. aeolicus IspE
was determined to 2.2 A˚ resolution (PDB code: 2VF3) [24]. Two molecules are
present in the asymmetric unit, featuring ‘‘active sites A and B.’’ Evidence for the
proposed binding mode of inhibitor 15 was provided by the cocrystal structure.
The water-soluble ligand indeed binds in the CDP-binding pocket. As a result
of the differences in amino-acid sequences of A. aeolicus and E. coli IspE [30],
the sulfonamide and nucleobase moieties form somewhat different H-bonding
patterns compared to those predicted by modeling. In particular, two additional
H bonds stabilize the cytosine moiety of ligand 15 (Figure 7.10a). The cytosine
moiety is engaged in four H bonds to the side chain and backbone amide of
His25 in active site B. The amino group forms an additional H bond to the
backbone amide C=O of Lys145. The cytosine ring is sandwiched by the side
chains of Tyr24 and Tyr175 (= Phe185 in E. coli IspE). A network of H bonds to
the side chains of Asn11, Tyr31, and Asp130 stabilizes the sulfonamide moiety
(Figure 7.10a).
Although AMP was present in the crystallization conditions, the electron density
observed in the glycine-rich loop of the ATP-binding pocket was incompatible with
this compound. Modeling and reﬁnement of the density as diphosphate proved
successful. The latter unit forms numerous H bonds to the backbone-amide NH
groups of the glycine-rich loop, in analogy to the diphosphatemoiety of AMP-PNP in
the crystal structure of the E. coli enzyme complex [20]. With one exception (Gly95),
all the backbone-amide NH moieties of glycine residues of the loop are involved in
H-bonding. The residues of the glycine-rich loop, which are not glycine, however,
do not participate in H-bonding interactions with diphosphate. This underlines
the importance of the presence of glycine residues in phosphate-binding pockets.
Presumably, glycine is ideally suited for the binding of phosphate groups in such
loops as it can adopt the required conformation to wrap the loop around the bound
phosphate group [38].
For future efforts aimed at the design of inhibitors for IspE from pathogens
such as P. falciparum or M. tuberculosis, the ﬁnding that the cyclopropyl substituent
of ligand 15 is accommodated in the hydrophobic pocket is of particular interest
(Figure 7.10b). Given that the change from Phe185 (in E. coli IspE) to Tyr175 (in
A. Aeolicus IspE) increases the hydrophilicity of the small pocket, the cyclopropyl
ring was not expected to be located in this subpocket as it precludes solvation of
the hydroxyl group of Tyr175. This is an important ﬁnding, given that the enzymes
from P. falciparum and M. tuberculosis possess a conserved tyrosine residue at this
position, and that – according to homology modeling – the phenolic hydroxyl
group is directed into the small pocket. The propargylic sulfonamide vector of this
class of inhibitors is therefore highly suitable for precisely addressing the phenolic
hydroxyl group in future design cycles.
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7.4.4
Lessons Learnt from the Cocrystal Structure
By designing water-soluble inhibitors and solving the cocrystal structure of one
ligand with A. aeolicus IspE, the suggested binding mode was validated. Thus,
the ﬁrst design cycle was successfully completed. The inhibitor occupies the
CDP-binding pocket and exhibits a Ki value in the lower micromolar activity range.
This proof of concept opens the way for further modiﬁcation and optimization of
the inhibitors aimed at the development of ligands with activity against IspE from
medically important organisms. Thus, the cocrystal structure solved represents an





The active site of the kinase IspE features both highly polar and hydrophobic
subpockets. Because the highly polar subpockets do not lend themselves well to
structure-based drug design, the inhibitors were targeted to the lipophilic regions
of the active site. Using structure-based design, the ﬁrst inhibitors of the enzyme
were developed, which display drug-like properties and highly satisfactory potency.
A number of conclusions can be drawn from the series of inhibitors:
• Inhibition of IspE is possiblewhilst bypassing the highly polar phosphate-binding
pocket in the absence of a phosphate moiety. Therefore, the ligands synthe-
sized constitute the ﬁrst potent and drug-like inhibitors of an enzyme of the
nonmevalonate pathway.
• The inhibitors target only the CDP-binding pocket, potentially affording better
selectivity than inhibitors designed to bind to the ATP-binding pocket.
• The majority of the binding free enthalpy is derived from the cytosine scaffold
and the propargylic sulfonamide vector.
• A systematic variation of the vector’s substituent provided access to SARs,
conﬁrming the proposed binding mode. In addition, these modiﬁcations gave
rise to the second example of the ‘‘55% rule’’ for the optimal ﬁlling of cavities
applied to an enzymatic context.
• Preparation of a water-soluble derivative enabled crystallographic studies of
an enzyme–inhibitor complex, validating the proposed binding mode. This
cocrystal structure provided invaluable structural information, especially in view
of ﬁne-tuning the ligands to obtain activity against the pathogenic enzymes.
In conclusion, the new target IspE revealed itself to be ideally suited to
structure-based inhibitor design. The inhibitors synthesized in the context of
this project represent a successful application of this design strategy.
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7.5.2
Outlook
The design and synthesis of the ﬁrst-generation inhibitors of IspE opened up a
number of future research avenues.
First, as a result of the observed difference in amino acid sequences between the
model system E. coli and the pathogenic enzymes – marked by the replacement
of the phenylalanine residue lining the hydrophobic pocket by a tyrosine – the
structure of the inhibitors will have to be ﬁne-tuned to address this structural
difference. Second, the bisubstrate approach could be tried to obtain even more
potent and selective inhibitors of IspE. In principle, it should be possible to decorate
the established scaffold to occupy the different pockets of the active site. Third,
it would be very rewarding to identify an attractive mimic in the quest for new
cytosine analogues. As opposed to the other nucleobases, very few cytosine substi-
tutes have been described to date. Finally, identiﬁcation of a generally applicable
way of rendering promising inhibitors water soluble without having to undertake
a time-consuming design cycle and synthesis of the new derivatives would be of
great interest. In this way, attractive structures could be designed, synthesized,
and assayed without worrying about their physicochemical properties such as
solubility.
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